Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Intravenous Solutions Market, by Region, 2019-2029 (USD Billion)
1.2.2. Intravenous Solutions Market, by Type, 2019-2029 (USD Billion)
1.2.3. Intravenous Solutions Market, by Solution Composition, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Intravenous Solutions Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Intravenous Solutions Market Dynamics
3.1. Intravenous Solutions Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rise in prevalence of malnutrition
3.1.1.2. Advancements and new innovations in the products for patient convenience
3.1.2. Market Challenges
3.1.2.1. Lack of experienced healthcare professionals
3.1.2.2. Complications of intravenous administration therapy
3.1.3. Market Opportunities
3.1.3.1. Growing geriatric population
Chapter 4. Global Intravenous Solutions Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Intravenous Solutions Market, by Type
6.1. Market Snapshot
6.2. Global Intravenous Solutions Market by Type, Performance – Potential Analysis
6.3. Global Intravenous Solutions Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
6.4. Intravenous Solutions Market, Sub Segment Analysis
6.4.1. Total Parenteral Nutrition
6.4.2. Peripheral Parenteral Nutrition
Chapter 7. Global Intravenous Solutions Market, by Solution Composition
7.1. Market Snapshot
7.2. Global Intravenous Solutions Market by Solution Composition, Performance – Potential Analysis
7.3. Global Intravenous Solutions Market Estimates & Forecasts by Solution Composition 2019-2029 (USD Billion)
7.4. Intravenous Solutions Market, Sub Segment Analysis
7.4.1. Saline
7.4.2. Carbohydrates
7.4.3. Vitamins and Minerals
7.4.4. Other Solution Compositions
Chapter 8. Global Intravenous Solutions Market, Regional Analysis
8.1. Intravenous Solutions Market, Regional Market Snapshot
8.2. North America Intravenous Solutions Market
8.2.1. U.S. Intravenous Solutions Market
8.2.1.1. Type breakdown estimates & forecasts, 2019-2029
8.2.1.2. Solution Composition breakdown estimates & forecasts, 2019-2029
8.2.2. Canada Intravenous Solutions Market
8.3. Europe Intravenous Solutions Market Snapshot
8.3.1. U.K. Intravenous Solutions Market
8.3.2. Germany Intravenous Solutions Market
8.3.3. France Intravenous Solutions Market
8.3.4. Spain Intravenous Solutions Market
8.3.5. Italy Intravenous Solutions Market
8.3.6. Rest of Europe Intravenous Solutions Market
8.4. Asia-Pacific Intravenous Solutions Market Snapshot
8.4.1. China Intravenous Solutions Market
8.4.2. India Intravenous Solutions Market
8.4.3. Japan Intravenous Solutions Market
8.4.4. Australia Intravenous Solutions Market
8.4.5. South Korea Intravenous Solutions Market
8.4.6. Rest of Asia Pacific Intravenous Solutions Market
8.5. Latin America Intravenous Solutions Market Snapshot
8.5.1. Brazil Intravenous Solutions Market
8.5.2. Mexico Intravenous Solutions Market
8.5.3. Rest of Latin America Intravenous Solutions Market
8.6. Rest of The World Intravenous Solutions Market
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Amanta Healthcare Ltd.
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Axa Parenterals Ltd.
9.2.3. B. Braun Melsungen AG
9.2.4. Baxter International Inc.
9.2.5. Dickinson and Company
9.2.6. Eurolife Healthcare Pvt Ltd.
9.2.7. Fresenius Kabi AG
9.2.8. Grifols S.A
9.2.9. Henry Schein Inc.
9.2.10. ICU Medical, Inc.
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/